Produktname:methyl 3-amino-6-bromopyrazine-2-carboxylate
IUPAC Name:methyl 3-amino-6-bromopyrazine-2-carboxylate
- CAS：6966-01-4
- Molekulare Formel：C6H6BrN3O2
- Reinheit：95%+
- Katalognummer：CM102385
- Molekulargewicht：232.04
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:6966-01-4
- Molekulare Formel:C6H6BrN3O2
- Schmelzpunkt:-
- SMILES-Code:O=C(C1=NC(Br)=CN=C1N)OC
- Dichte:
- Katalognummer:CM102385
- Molekulargewicht:232.04
- Siedepunkt:322.4°C at 760 mmHg
- Mdl-Nr.:MFCD00834964
- Lagerung:Keep in dark place, store at 2-8°C.
Category Infos
- Pyrazines
- Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.
- pyrazine,pyrazine price
- if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.
Column Infos
- Darovasertib
- The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Darovasertib, a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma”. Uveal melanoma (UM) is the most common primary intraocular malignancy. About half of primary uveal melanoma tumors metastasize but with no standard treatment. Most patients with metastatic uveal melanoma have been found to have mutations in GNAQ or GNA11, that are associated with consistent activation of the protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways.
IDEAYA's Darovasertib (IDE196) is a potent, selective small molecule inhibitor of PKC which stops activating PKC/MEK pathway. Darovasertib is under Phase 2 expansion and Phase 3 registrational trial with Crizotinib in GNAQ/11 metastatic cutaneous melanoma.
Suche 
+86 21 5895 0110 
